||COM USD0.0001 REGS
||EPS - Basic
||Market Cap (m)
Napo Pharm.Regs Share Discussion Threads
Showing 151 to 172 of 175 messages
|finally! market agrees !|
|Back down to where this thread started from!|
You still here, very dissapointing performance from my original purchase! Unlikely I will ever get that back!!|
|groats - I also bought a few more a couple of weeks ago.|
|Nice, tick up before close. Very interesting!
U got a target price for these?|
|That 30k is a buy :)-
Monis, how long you been in these?|
|Perhaps they were sells but have immediately found a new home via a market maker thus no fall nor rise ie those buys we can see have been bought from the 200,000 seller. Still positive.|
|groats - what do you think now...|
|I don't know they are buys, I said trades not buys. They do seem strange but if they are sells why no drop in price? I don't know how to interpret them.
The 75,000 looks like a buy though.|
How do you know they are buys? I bought £1200 worth a couple of days back and had to pay full offer price, I can't see how they getting mid-price for that quantity. I would say they are sells|
|make that three...|
|two big trades today.|
|25,000 buy at the end of the day by the look of things.|
|few buys as thought.
groats- I think it's good news, dyor of cause.|
Are you the only shareholder in these???
How will America take this news iyo?|
|Would expect to see more buying from the states this afternoon.|
|Napo Pharma raises $2.1 mln net from convertible debt and share issues
LONDON (Thomson Financial) - Napo Pharmaceuticals Inc. said it has raised
around $2.1 million gross through the issue of convertible debt and shares.
The company also said it has now progressed commercial license talks with at
least two potential partners for its crofelemer diarrhoea treatment.
"We are pleased to announce this fundraising and the financial strength it
provides Napo to complete our corporate licensing discussions while continuing
with the progress of our final Phase 3 clinical trial for CRO-HIV and all NDA
related activities," chief executive Lisa Conte said.
The directors are confident that the Company will be able to secure a partnership for the commercial rights to crofelemer which will provide sufficient resources to the Company to fund the development of CRO-HIV through to FDA approval.
The Company has now progressed commercial license discussions with at least two potential partners, with customary commercial pharmaceutical license provisions including development costs, milestones, and royalty payments. Any license agreement will be subject to mutual diligence and a definitive agreement.
|RNS out - excellent news re funding and discussions for potential partnerships imo.|
|another buy reported on the bell.|
|Looks like a few more delayed buys are going to come through.|